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Abstract Rat insulinoma 1046-38 cells represent a model
system to study L-cell function. The mRNAs for sst1 and sst2,
two of the five somatostatin receptors, were detected by reverse
transcription polymerase chain reaction amplification in these
cells. Displacement binding analysis suggested that sst1 repre-
sents the major somatostatin receptor subtype. The sst1 selective
compound CH-275 did not inhibit adenylyl cyclases while
compounds that activated sst2 did. In contrast, CH-275 caused
a marked inhibition of voltage-operated Ca2+ channels while the
sst2 specific analog octreotide elicited a less pronounced effect
suggesting that in rat insulinoma 1046-38 cells sst1 preferably
mediates the inhibition of Ca2+ channels.
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1. Introduction
The inhibitory neuropeptide, somatostatin (SST), occurs in
at least two biologically active forms, SST-14 and the N-ter-
minally elongated SST-28, and displays a broad anatomical
distribution [1]. Both SST peptides mediate similar physiolog-
ical actions such as the inhibition of hormone release from a
variety of di¡erent neuroendocrine cells, of exocrine secretion
and gut motility and they function as neuromodulators in the
central nervous system [2,3]. SST acts on at least ¢ve soma-
tostatin receptor subtypes (ssts) that are products from dis-
tinct genes [4]. Moreover, the sst2 subtype occurs in two var-
iants that di¡er in their carboxy-terminal tails, sst2A and
sst2B, that result from alternative splicing [5]. Sequence rela-
tionship and pharmacology indicated that the somatostatin
receptor family is divided into two subfamilies comprising
sst1, sst4 and sst2, and sst3 and sst5, respectively [6]. All
ssts bind SST-14 and -28 with high a⁄nity and little selectivity
although moderate preferential binding of SST-28 has been
reported for rat and human sst5 [4,6,7]. The ssts di¡er, how-
ever, in their a⁄nity for synthetic peptides. For instance, oc-
treotide represents a key ligand with clear selectivity for sst2
[6] and CH-275 the only analog with selectivity for sst1 [8].
No sst3 and sst4 selective compounds are available to date [9].
When expressed in cell lines ssts are coupled to a variety of
cellular e¡ectors. In the case of sst1, sst2 and sst4 coupling to
adenylyl cyclases (AC) has been observed or not while sst3
and sst5 have consistently been shown to lower cAMP levels
[4]. The observed di¡erential coupling to AC of sst2A and
sst2B [10] and di¡erent cellular environments for sst1 and
sst4 may account for the discrepancies. Moreover, all ssts
activate phospholipase C-L and involvement in serine/threo-
nine or phosphotyrosine dephosphorylation has been ob-
served for sst1, sst2 and sst5 [4,11]. sst2 and sst3 have been
reported to modulate ion channels. In particular, sst2 has
been demonstrated to inhibit Ca2 currents, highlighting its
importance in endocrine regulation [4,6]. In contrast, inhibi-
tion of Ca2 channels by sst1 has not been observed so far.
Here we report that neuroendocrine RIN1046-38 cells pos-
sess sst1 and sst2 somatostatin receptors and that sst2 selec-
tive peptides cause strong inhibition of AC while the sst1
preferring compound CH-275 did almost not inhibit AC.
Quite in contrast, this compound caused stronger inhibition
of voltage-activated Ca2 channels than sst2 selective pepti-
des. These results suggest that in RIN1046-38 cells the soma-
tostatin receptor subtype 1 causes inhibition of Ca2 channels
and hence may play a role in endocrine regulation.
2. Materials and methods
2.1. Reverse transcriptase polymerase chain reaction ampli¢cation
RIN1046-38 cells were grown in RPMI 1640 medium supplemented
with 25 mM HEPES, 5% fetal calf serum and 5% newborn serum.
Cells (50^100 mg) were collected by low speed centrifugation and
homogenized in RNAzol (AGS, Heidelberg, Germany) and isolation
of RNA, cDNA synthesis, and PCR of sst1^sst5 cDNA fragments,
blotting and hybridization to 32P-labeled sst subtype speci¢c oligonu-
cleotides were performed essentially as described previously [12].
2.2. Membrane preparation and ligand binding
Cells were harvested and membranes prepared as described [12].
The membrane fraction was suspended in 1 ml of the same bu¡er
per 175 cm2 cell culture £ask, the protein concentration determined
using a protein assay kit (BioRad, Munich, Germany) and frozen in
10-Wl aliquots in liquid nitrogen. Ligand binding was performed [12]
using 7.5 Wg membrane protein per assay. Bound radiolabeled peptide
was measured in a Q-counter (Canberra Packard, Dreieich, Germany).
Background binding was determined in the presence of 10 WM SST-
14. Calculations were carried out using SigmaPlot.
2.3. cAMP assays
For the determination of intracellular cAMP levels cells were plated
the day before into 24-well microtiter plates and incubated in serum-
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free medium with 0.5 mM 3-isobutyl 1-methylxanthine. Ten minutes
later 25 WM forskolin was added together with or without peptide
agonists at the indicated concentrations. After 45 min, incubations
were terminated by the addition of ethanol (320‡C) to 70%. Follow-
ing extraction at 320‡C for 14 h the supernatant was removed from
the cells and the solvent evaporated. The remainder was dissolved in
cAMP assay bu¡er and subjected to cAMP determinations as recom-
mended by the manufacturer (Amersham, Braunschweig, Germany).
2.4. Electrophysiological recordings
Voltage-clamp recordings were obtained using the whole-cell mode
of the patch-clamp technique [13]. Small coverslips with adherent cells
were placed into a recording chamber (0.3 ml) mounted on an in-
verted microscope (Axiovert 100, Zeiss, Jena, Germany). Cells were
continuously perfused at room temperature (22^24‡C) with a standard
external solution which comprised: 130 mM NaCl, 5.4 mM KCl,
1 mM CaCl2, 1 mM MgCl2, 10 mM glucose, and 10 mM HEPES
(pH 7.3). Patch pipettes were pulled from borosilicate capillary glass
(Hilgenberg, Malsfeld, Germany). The pipettes had an initial resist-
ance of 7 to 10 M6 when ¢lled with a solution containing 130 mM
CsCl, 4 mM MgCl2, 3 mM ATP, 10 mM EGTA, 10 mM HEPES (pH
7.3). Seal resistances s 10 G6 were routinely obtained by applying
gentle suction to the pipettes. Membrane rupture was monitored elec-
trically as an increase in capacitance. Pipette capacitance, membrane
capacitance, and series resistance were electronically compensated to
achieve minimal capacitive currents [14]. Cell responses were recorded
by an Axopatch 200 A ampli¢er (Axon Instruments, Inc., Foster City,
CA, USA). A 486 computer in combination with the ISO 2 patch-
clamp software (MFK, Niedernhausen, Germany) was used for data
acquisition and analysis. Whole-cell currents were ¢ltered at 1 kHz.
Currents were corrected for linear leakage and capacitive components
before being digitized and stored by the computer at a sampling rate
of 5 kHz. To isolate inward currents through voltage-gated calcium
channels, barium was used as charge carrier in a sodium- and potas-
sium-free solution consisting of: 120 mM N-methyl-D-glucosamine,
10.8 mM BaCl2, 5.4 mM CsCl, 1 mM MgCl2, 10 mM glucose,
10 mM HEPES (pH 7.3).
3. Results and discussion
3.1. Identi¢cation of ssts in RIN1046-38 cells
Polymerase chain reaction ampli¢cation experiments, DNA
blotting and hybridization of the ampli¢ed fragments with
receptor subtype speci¢c probes [12] were carried out in order
to determine which particular ssts might be present in
RIN1046-38 cells. The observed size of the detected fragments
of about 320 bp and 330 bp using sst1 and sst2 speci¢c oli-
gonucleotides corresponded to the predicted fragment sizes of
318 and 332 bp. It is therefore concluded that these cells
contain mRNAs for sst1 and sst2 (Fig. 1). However, the
band corresponding to sst1 mRNA appears to be much
more intense than that corresponding to sst2 mRNA. Other
bands have not been detected. This observation suggests that
RIN1046-38 cells likely contain a dual somatostatin receptor
population consisting primarily of sst1 and to a lesser extent
of sst2. The sst mRNAs appear to be translated into func-
tional receptors since RIN1046-38 cells contain high a⁄nity
binding sites for 125I-Tyr11-somatostatin-14 [15]. Displacement
binding experiments have been used to identify which sst sub-
types contribute to the population of somatostatin receptors
(Fig. 2). The two naturally occurring peptides, SST-14 and
SST-28, were about equally potent to displace the radioligand.
Since sst5 shows slightly higher a⁄nity for SST-28 [4,6,7] it
appears unlikely that RIN1046-38 cells contain high levels of
this subtype. Octreotide which has high a⁄nity for rat sst2
(Ki = 2 nM) and moderate a⁄nity for rat sst3 and sst5 (14 and
17 nM, respectively) [9] displays an IC50 value of 300 nM. No
partial displacement of the radioligand was observed at lower
concentrations of the competitor. These results exclude the
possibility that the sst2, sst3 and sst5 subtypes represent the
major somatostatin receptor in RIN1046-38 cells. However,
the sst1 preferring analog CH-275 [8] which displays an IC50
value of 46 nM in human embryonic kidney cells transfected
with sst1 cDNA completely displaced the radioligand from
RIN1046-38 cell membranes with a similar IC50 value
(51 þ 10 nM). CH-275 has been demonstrated to be of at least
5-fold or 10-fold lower a⁄nity at rat sst5 or sst4, and of even
lower a⁄nity at the other rat sst subtypes [12]. Therefore, sst1
represents most likely the major somatostatin receptor in
RIN1046-38 cells. The reasonable correlation of the IC50 val-
ues of the somatostatin analogs BIM23052, BIM23268 and
BIM23295 (Fig. 2) observed in RIN1046-38 cells with their
IC50 values obtained using cell lines transfected with sst1
cDNA [9] (51, 5.7 and 4.7 nM vs. 97, 12 and 5.4 nM) also
supports this conclusion. To date there is no sst4 selective
analog available [4,6,9] which can be used to directly rule
out the possibility that sst4 receptors are present in
RIN1046-38 cells. However, the observed lack of sst4
mRNA is indicative of the absence of the sst4 subtype. Taken
together these ¢ndings suggest that the vast majority of so-
matostatin receptors in the membranes of RIN1046-38 cells
are of the sst1 subtype.
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Fig. 1. DNA blot analysis of somatostatin receptor cDNA frag-
ments following RT-PCR ampli¢cation, agarose gel electrophoresis
and transfer to nylon membranes. Ampli¢cation reactions were car-
ried out with sst speci¢c primers using either cDNA (cDNA) or, for
control of contamination with genomic or other DNA, with RNA
(RNA) or in the absence of a DNA template (H20). The fragment
lengths of a size standard run in parallel are indicated on the left.
Fig. 2. Displacement of 125I-Tyr11-SST-14 from RIN1046-38 cell
membranes by various SST analogs. The data represent one typical
of three independent experiments performed in duplicate. The data
were ¢tted by non-linear regression using the SigmaPlot program.
Observed IC50 values were 1.4 þ 0.2 nM for SST-28 (¢lled circles),
1.8 þ 0.3 nM for SST-14 (open triangles), 4.7 þ 0.5 nM for
BIM23295 (¢lled squares), 5.4 þ 0.7 nM for BIM23268 (open
circles), 14 þ 2 nM for BIM23052 (open squares), 51 þ 10 nM for
CH-275 (diamonds) and 238 þ 34 nM for octreotide (¢lled triangles).
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3.2. Coupling of sst2 but not sst1 to the inhibition of AC
Application of SST-14 and SST-28 caused a severe inhibi-
tion of forskolin-stimulated AC (Fig. 3). Surprisingly a similar
response was also seen when the cells were stimulated with
octreotide. This observation is in line with the observed low
abundance of sst2 mRNA and suggests that RIN1046-38 cells
contain a marginal population of sst2 receptors. Apparently,
this is too low to be detected in the displacement binding
experiments. The small number of sst2, however, su⁄ces to
induce a strong inhibition of AC. Consistent with this as-
sumption is the observation that the compounds BIM23052,
BIM23268 and BIM23295 inhibited AC at concentrations (80
nM, 30 nM, 100 nM, respectively) that correspond reasonably
to their a⁄nities at sst2 (69 nM, 101 nM, 163 nM, respec-
tively) [9,12]. The high IC50 values of these compounds also
indicate that the inhibition of AC is not mediated by sst3 or
sst5 which have 10- to 100-fold higher a⁄nity for these ana-
logs [9]. The sst1 preferring analog CH-275 caused only a
small inhibition of AC at very high concentrations. In this
high concentration range the sst2 subtype may bind and hence
be activated by CH-275. Thus, it is concluded that the inhib-
ition of AC in RIN1046-38 cells is mediated by sst2 and not
by sst1 somatostatin receptors.
3.3. sst1 and sst2 mediate inhibition of voltage-activated
Ca2+ channels
Electrophysiological recordings (n = 12 cells) have been car-
ried out to analyze whether SST or its analogs can cause
inhibition of voltage-activated Ca2 channels and which sst
subtype may be involved. Fig. 4 shows that 10 nM SST-14
reduced inward Ba2 currents through voltage-activated Ca2
channels by 12^53% (n = 8; Fig. 4A). Six of these cells re-
sponded to application of CH-275 with a 18^34% inhibition
of Ca2 channels (Fig. 4B). Three of these cells that were
responsive to SST-14 and CH-275 were also tested with oc-
treotide. This analog reduced inward Ba2 currents through
voltage-activated Ca2 channels similar to SST-14 and CH-
275 in all three cells. Four other cells that responded to CH-
275 challenge with the inhibition of Ca2 channels (15^48%)
but were not tested with SST-14 were also exposed to octreo-
tide. This compound induced a weaker response in these cells
(10^18%; Fig. 4C). Thus the sst1 preferring compound CH-
275 caused a marked inhibition of voltage-activated Ca2
channels in RIN1046-38 cells that exceeded that induced by
octreotide. Therefore, the results suggest that in addition to
sst2 and sst5 also the sst1 subtype can functionally couple to
Ca2 channels.
The ¢nding that sst1 mediates inhibition of voltage-gated
Ca2 channels is rather surprising. Firstly, because it has been
shown that in another insulin-secreting rat insulinoma cell
line, RINm5F cells, the sst2 subtype mediated inhibition of
voltage-activated Ca2 currents [16]. Secondly, because trans-
fection of sst1 cDNA in RINm5F cells did not lead to SST-
induced inhibition of voltage-gated Ca2 channels while trans-
fection of sst2 cDNA did [17]. To rule out that an as yet
unidenti¢ed receptor displays a pharmacology similar to sst1
and mediates the inhibition of Ca2 currents, the cDNA frag-
ment ampli¢ed with the sst1 speci¢c primers was subcloned
and sequenced (results not shown). Six from seven sequences
di¡ered in nine nucleotide positions from the published DNA
sequence [18] without changing the amino acid sequence. The
seventh sequence displayed in addition an A to C transversion
in codon 306 resulting in the exchange of glutamine for pro-
line. Whether this sequence corresponds to an allelic variant
of sst1 or represents a PCR artifact remains unknown. In the
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Fig. 4. Inhibition of voltage-activated inward Ba2 currents through
voltage-activated Ca2 currents by SST peptides. Cells were voltage-
clamped at 380 mV and depolarized to 0 mV for 100 ms before
and during peptide application as well as after washing out of the
peptide. Representative current traces are depicted. Current traces
obtained from one cell are shown superimposed. A: response to
SST-14; B: response to CH-275; C: response to CH-275 or octreo-
tide.
Fig. 3. Dose^response relationship for the inhibition of forskolin-
stimulated adenylyl cyclase by various SST analogs. The data are
the mean of three independent experiments that have been carried
out in triplicate. The data were ¢tted by non-linear regression using
the SigmaPlot program. SST14 (EC50 = 0.3 nM; open triangles),
SST-28 (EC50 = 0.7 nM; ¢lled circles), octreotide (EC50 = 1 nM,
¢lled triangles), BIM23268 (EC50 = 30 nM; open circles), BIM23295
(EC50 = 100 nM; ¢lled squares), BIM23052 (EC50 = 80 nM; open
squares) and CH-275 (EC50 cannot be determined due to incomplete
inhibition at very high peptide concentrations; diamonds).
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former case the mutation would be localized in the third ex-
tracellular loop. It has been demonstrated that in sst1 this
region contains important determinants that are responsible
for hexapeptide and octapeptide binding while binding of
SST-14 and CH-275 depends on determinants present in the
second extracellular loop [19,20]. Therefore, it seems highly
unlikely that a mutant sst1 receptor with an altered pharma-
cology accounts for our observations. It is also unlikely that
another unidenti¢ed receptor that would not be ampli¢ed with
sst1 speci¢c primers mediates the inhibition of calcium chan-
nels. The closest relatives of somatostatin receptors are the
opioid receptors. It is known that these receptors do bind
SST analogs. They are, however, cyclic octapeptides [21].
CH-275 comprises eleven amino acids [8]. In RINm5F cells
a speci¢c G protein trimer, GKo2/L1/Q3, couples SST via the
sst2 to the inhibition of voltage-activated Ca2 currents [16].
It could be that in RIN1046-38 cells another G protein trimer
couples the sst1 to this cellular e¡ector. Alternatively, sst1-
mediated inhibition of Ca2 channels could proceed through
a completely di¡erent pathway. Nonetheless, the inhibition of
voltage-activated Ca2 currents by sst1 observed in the
present report points to an importance of this receptor sub-
type in endocrine regulation.
It has been reported [22] that in neocortical membranes at
least two types of somatostatin binding sites are present: one,
termed SS-1 or SRIF-1, with high a⁄nity for SST-14 and the
synthetic ligand MK-678; and another one, SS-2 or SRIF-2,
with high a⁄nity for SST-14 and the analog CGP23996
[23,24]. Both analogs, MK-678 and CGP23996, mediated
the inhibition of voltage-activated Ca2 channels in these cells
while only the former additionally potentiated a potassium
conductance [22]. Later on the pharmacological identity be-
tween somatostatin SS-2 binding sites and the sst1 somato-
statin receptor subtype has been demonstrated [25]. These
¢ndings suggest that in addition to the sst1-mediated inhibi-
tion of voltage-activated Ca2 channels in RIN1046-38 cells
the same subtype may also elicit the inhibition of voltage-
activated Ca2 channels in rat neocortical neurons.
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